A5073649680- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Cancer Genomics and Diagnostics
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metabolism, Diabetes, and Cancer
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Cancer-related Molecular Pathways
- Ferroptosis and cancer prognosis
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Lung Cancer Research Studies
- Lymphoma Diagnosis and Treatment
- Extracellular vesicles in disease
- Cancer Risks and Factors
- Metastasis and carcinoma case studies
- Salivary Gland Tumors Diagnosis and Treatment
- Hepatitis B Virus Studies
Istituti Clinici Scientifici Maugeri
2010-2024
Clinical Research Institute
2024
Fondazione Salvatore Maugeri
2011-2023
University of Pavia
2021-2022
ASST Fatebenefratelli Sacco
2019
Azienda Ospedaliera Ospedale Civile di Legnano
2019
Aziende Socio Sanitarie Territoriale Ovest Milanese
2019
Istituti di Ricovero e Cura a Carattere Scientifico
2010
Lombardy was the first area in Italy to have an outbreak of coronavirus disease 19 (COVID-19) at beginning 2020. In this context, cancer has been reported as a major risk factor for adverse outcomes and death, so oncology societies quickly released guidelines on care during pandemic. The aim study investigate management patients oncological treatments COVID-19 pandemic describe containment measures performed our outpatient clinic Pavia (Lombardy). A comparison with same period four previous...
Immune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic predictive value in many solid tumors. In this study, we aimed to investigate the role of these predicting distant relapse breast cancer patients treated with neoadjuvant chemotherapy (NACT). All who referred our Breast Unit underwent NACT were retrospectively reviewed. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR),...
A prospective, multicenter trial was undertaken to assess the activity, safety, and quality of life nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer (MBC).Fifty-two women with HER2-negative MBC who were candidates for disease enrolled treated at three centers Northern Italy. All patients had previously received taxane-based adjuvant or first-line setting. Single-agent nab-paclitaxel given dose 260...
The outcome of patients with metastatic breast cancer (MBC) has clearly improved over the past decades and proportion women living their disease for several years is increasing. However, usefulness multiple lines treatment still debated under evaluation. available data from both randomized trials large retrospective series are reviewed discussed in order to analyze management practices, emphasis on potential prognostic predictive factors clinical outcome. At present, evidence-based medicine...
Abstract Purpose Preliminary reports suggest that extracellular vesicles (EVs) might be a promising biomarker for breast cancer (BC). However, the quantification of plasmatic levels EVs is complex task. To overcome these limitations, we developed new, fast, and easy to use assay directly in plasma based on Single-Molecule Array (SiMoA). Methods By using SiMoA identify CD9+/CD63+ EVs, analyzed samples 181 subjects (95 BC 86 healthy controls, HC). A calibration curve, made serial dilution...
Background: The CDK4/6 inhibitor palbociclib combined with endocrine therapy (ET) has proven to prolong progression-free survival (PFS) in women hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC). Few data are available regarding the efficacy of such a regimen outside clinical trials. Patients and methods: This is multicentre prospective real-world experience aimed at verifying outcome plus ET an unselected population MBC...
Fulvestrant 500 mg (F500) is the most active endocrine single agent in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Few data are available regarding effectiveness of drug a real-world setting.This prospective, multicenter cohort study aimed to describe patterns treatment and performance F500 large population unselected women with MBC, focusing on potential prognostic or predictive factors for disease outcome response. The primary endpoints were...
DPD is the rate-limiting enzyme involved in metabolism of 5-fluorouracil and its prodrugs, capecitabine tegafur. Many cases severe toxicities by fluoropyrimidines are reported literature, sometimes with lethal outcome, due to a poor or null metabolizer phenotype. The exon 14-skipping mutation IVS14+1G>A c.2846A>T most common deficient variants. However, many additional variants DPYD gene unclear functional significance have been reported. We describe patient metastatic breast cancer who...
The host's immune system plays a crucial role in determining the clinical outcome of many cancers, including breast cancer. Peripheral blood neutrophils and lymphocytes counts may be surrogate markers systemic inflammation potentially reflect survival outcomes. aim present study is to assess preoperative inflammatory biomarkers predict local or distant relapse In particular we investigated ER+ HER2- early cancer, considering its challenging risk stratification. A total 1,763 cancer patients...
Clinical complexity (CC) is an increasingly recognized feature of internal medicine patients who are often characterized by complex needs determined both biological (i.e. intrinsic to the patient or disease biology) and non-biological socioeconomic, cultural, environmental, behavioural) factors. Breast cancer, one most common malignancies worldwide, certainly represents example a disease. Nonetheless, concept itself CC its possible determinants in breast cancer have been poorly addressed. We...
Background: Progesterone receptor (PgR) negative breast cancer (BC) is an aggressive subtype with poor prognosis and reduced response to endocrine treatments. Several studies have suggested that androgen (AR) expression associated a favorable tumor biology, longer recurrence free survival (RFS), overall survival. In the literature no data exist regarding role of AR in early stage estrogen (ER)+/PgR– BCs. The aim this study was evaluate prognostic setting. Patients methods: This monocentric...
// Alessandro Broccoli 1 , Beatrice Casadei Alice Morigi Federico Sottotetti 2 Manuel Gotti 3 Michele Spina 4 Stefano Volpetti 5 Simone Ferrero 6 Francesco 7 Pisani 8 Merli 9 Carlo Visco 10 Rossella Paolini 11 Vittorio Ruggero Zilioli 12 Luca Baldini 13 Nicola Di Renzo 14 Patrizia Tosi 15 Cascavilla 16 Molica 17 Fiorella Ilariucci 18 Gian Matteo Rigolin 19 D'Alò 20 Anna Vanazzi 21 Elisa Santambrogio 22 Roberto Marasca 23 Lucia Mastrullo 24 Claudia Castellino 25 Giovanni Desabbata 26 Ilaria...
Growing evidence suggests that sublobar resections offer more favorable outcomes than lobectomy in early-stage lung cancer surgery. However, a percentage of cases cannot be ignored develops disease recurrence irrespective the surgery performed with curative intent. The goal this work is thus to compare different surgical approaches, namely, and segmentectomy (typical atypical) derive prognostic predictive markers. Here we analyzed cohort 153 NSCLC patients clinical stage TNM I who underwent...